2018-004149-17: A randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment. |
|
|
| Not yet recruiting | 1/2 | 54 | Europe | JNJ-40346527-AAC-G-002, JNJ-40346527-AAC-G-002, Capsule, hard | University of Oxford / Clinical Trials and Research Governance, Wellcome Trust, Janssen Pharmaceutica NV | Mild Cognitive Impairment, Diseases [C] - Nervous System Diseases [C10] | | | | |
MICAD, NCT04121208: MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease |
|
|
| Terminated | 1 | 2 | Europe | JNJ-40346527, Placebo | University of Oxford, Janssen Pharmaceutica | Alzheimer Disease, Mild Cognitive Impairment | 02/22 | 02/22 | | |
NCT03177460: Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer |
|
|
| Completed | 1 | 33 | US | Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, FMS Inhibitor JNJ-40346527, JNJ-40346527, Radical Prostatectomy, Prostatovesiculectomy | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Testosterone Greater Than 150 ng/dL | 01/24 | 01/24 | | |
